US Market Mulls Next-Day Settlement Options

Elements of the market consider capitalizing on the momentum gained after its recent T+2 move.

Sibos 2017
Naturally, there are practical concerns around moving to T+1 or T+0, but the DTCC is adamant that technology is not one of them.

The US shortened its settlement cycle from three days after execution, or T+3, to T+2 on September 5. That process, overseen by the Depository Trust and Clearing Corp. (DTCC), the Securities Industry and Financial Markets Association (Sifma), and the Investment Company Institute (ICI), largely passed without problems, but the work required to accomplish it has reportedly left some participants wondering whether they should go further.

“There’s a lot of talk about T+1,” John Abel, executive

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

If you already have an account, please sign in here.

Brown Brothers Harriman unifies busy suite of AI products

It’s a new world, contend BBH’s Kevin Welch and Josh Fine. After a few years of experimentation that yielded several AI products for the bank and its clients, it was time to put the puzzle pieces together to serve a different way of working post-Covid.

Bank-backed Versana takes aim at syndicated loan tech

Born from a consortium that includes JP Morgan and Bank of America, Versana aims to bring up-to-date and permissioned data to the syndicated loan market—the first step to a more transparent and faster operating market.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: